Mirabegron

Drug Profile

Mirabegron

Alternative Names: Betanis; Betmiga; Myrbetriq; YM 178; YM-128

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Acetamides; Ethanolamines; Small molecules; Thiazoles
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Phase III Interstitial cystitis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 01 Aug 2016 Phase-III clinical trials in Interstitial cystitis in USA (PO) (NCT02787083)
  • 01 Jun 2016 Phase-III clinical trials in Overactive bladder (In adolescents, In children) in Belgium and Denmark(PO,controlled-release) (NCT02751931; EudraCT2015-002876-25)
  • 07 Apr 2016 Phase-III clinical trials in Overactive bladder (In adolescents, In children) in Lithuania (PO,controlled-release) (EudraCT2015-002876-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top